US EditionjCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RP
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RP
jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 50% higher than the highest dose administered in prior jCyte trials. “The initiation of patient dosing in this trial marks an important milestone in our mission to bring a breakthrough …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
